FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947559080> ?p ?o ?g. }

• W2947559080 endingPage "1091" @default.
• W2947559080 startingPage "1091" @default.
• W2947559080 abstract "1091 Background: Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)-pathway is frequently activated in HER2-negative breast cancer and may play a role in taxane-resistance. LY is a dual inhibitor of p70 S6 kinase and AKT. TAKTIC study aimed to determine the recommended phase II dose (RP2D) of the combination of LY with wP (phase Ib) and to estimate overall response rate (ORR) of this regimen (phase II) in HER2-negative LA or MBC patients, both in the overall patient population and in patients with activation of PI3K/AKT pathway (PI3KAKT+). Methods: HER2-negative inoperable LA or MBC patients (pts), with (phase Ib) or without (phase II) previous cytotoxic treatment for advanced disease were eligible. Oral LY (400 or 500mg) was administered daily in combination with intravenous wP (70 or 80mg/m 2 ). A modified CRM using an adaptive Bayesian model guided the dose escalation of both agents. PI3KAKT+ was defined as activating mutation of PIK3CA and/or AKT by targeted NGS or homozygous loss of PTEN by array comparative genomic hybridization (aCGH) or loss of PTEN by immunohistochemistry, as evaluated on available fresh tumor tissue. Results: A total of 12 and 35 patients (pts) were included in the phase Ib and II, respectively. In phase Ib, only 1 dose-limiting toxicity (confusion) was observed at the last dose level (LY, 500 + wP, 80), which was determined as RP2D. Main drug-related adverse events (AE) in phase Ib were skin toxicity (92% of pts, G3-4 in 33%), and paresthesia (50% of pts, G3-4 in 8%). In the phase II study, ORR was 62.9 % [44.9,78.5] including 1 CR and 21 PR in the overall population and 55.6 % [30.8,78.5] in PI3KAKT+ pts (10 PR in 18 pts). Median progression-free survival was 12.4 months [7.9,17.9] and 6-month clinical benefit rate was 82.9% [66.4,93.4]. AEs in phase II were similar to phase I part, except that 17% of pts experienced pneumonia (G3-4 in 9%). Conclusions: Combining LY and wP in HER2-negative LA or MBC was feasible with preliminary evidences of efficacy, independently of PI3K/AKT activation. Clinical trial information: NCT01980277." @default.
• W2947559080 created "2019-06-07" @default.
• W2947559080 creator A5006642161 @default.
• W2947559080 creator A5011917700 @default.
• W2947559080 creator A5036751778 @default.
• W2947559080 creator A5043993292 @default.
• W2947559080 creator A5046670297 @default.
• W2947559080 creator A5047255645 @default.
• W2947559080 creator A5049369439 @default.
• W2947559080 creator A5053713474 @default.
• W2947559080 creator A5058791215 @default.
• W2947559080 creator A5069960152 @default.
• W2947559080 creator A5071553983 @default.
• W2947559080 creator A5072465879 @default.
• W2947559080 creator A5075116389 @default.
• W2947559080 creator A5082347575 @default.
• W2947559080 creator A5084322536 @default.
• W2947559080 creator A5089508487 @default.
• W2947559080 date "2019-05-20" @default.
• W2947559080 modified "2023-10-17" @default.
• W2947559080 title "TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in HER2-negative locally advanced (LA) or metastatic breast cancer (MBC) patients." @default.
• W2947559080 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.1091" @default.
• W2947559080 hasPublicationYear "2019" @default.
• W2947559080 type Work @default.
• W2947559080 sameAs 2947559080 @default.
• W2947559080 citedByCount "5" @default.
• W2947559080 countsByYear W29475590802019 @default.
• W2947559080 countsByYear W29475590802021 @default.
• W2947559080 countsByYear W29475590802022 @default.
• W2947559080 crossrefType "journal-article" @default.
• W2947559080 hasAuthorship W2947559080A5006642161 @default.
• W2947559080 hasAuthorship W2947559080A5011917700 @default.
• W2947559080 hasAuthorship W2947559080A5036751778 @default.
• W2947559080 hasAuthorship W2947559080A5043993292 @default.
• W2947559080 hasAuthorship W2947559080A5046670297 @default.
• W2947559080 hasAuthorship W2947559080A5047255645 @default.
• W2947559080 hasAuthorship W2947559080A5049369439 @default.
• W2947559080 hasAuthorship W2947559080A5053713474 @default.
• W2947559080 hasAuthorship W2947559080A5058791215 @default.
• W2947559080 hasAuthorship W2947559080A5069960152 @default.
• W2947559080 hasAuthorship W2947559080A5071553983 @default.
• W2947559080 hasAuthorship W2947559080A5072465879 @default.
• W2947559080 hasAuthorship W2947559080A5075116389 @default.
• W2947559080 hasAuthorship W2947559080A5082347575 @default.
• W2947559080 hasAuthorship W2947559080A5084322536 @default.
• W2947559080 hasAuthorship W2947559080A5089508487 @default.
• W2947559080 hasConcept C121608353 @default.
• W2947559080 hasConcept C126322002 @default.
• W2947559080 hasConcept C143998085 @default.
• W2947559080 hasConcept C185592680 @default.
• W2947559080 hasConcept C190283241 @default.
• W2947559080 hasConcept C2775930923 @default.
• W2947559080 hasConcept C2777511904 @default.
• W2947559080 hasConcept C2777609662 @default.
• W2947559080 hasConcept C2781413609 @default.
• W2947559080 hasConcept C2908647359 @default.
• W2947559080 hasConcept C29730261 @default.
• W2947559080 hasConcept C31760486 @default.
• W2947559080 hasConcept C530470458 @default.
• W2947559080 hasConcept C55493867 @default.
• W2947559080 hasConcept C71924100 @default.
• W2947559080 hasConcept C86554907 @default.
• W2947559080 hasConcept C90924648 @default.
• W2947559080 hasConcept C99454951 @default.
• W2947559080 hasConceptScore W2947559080C121608353 @default.
• W2947559080 hasConceptScore W2947559080C126322002 @default.
• W2947559080 hasConceptScore W2947559080C143998085 @default.
• W2947559080 hasConceptScore W2947559080C185592680 @default.
• W2947559080 hasConceptScore W2947559080C190283241 @default.
• W2947559080 hasConceptScore W2947559080C2775930923 @default.
• W2947559080 hasConceptScore W2947559080C2777511904 @default.
• W2947559080 hasConceptScore W2947559080C2777609662 @default.
• W2947559080 hasConceptScore W2947559080C2781413609 @default.
• W2947559080 hasConceptScore W2947559080C2908647359 @default.
• W2947559080 hasConceptScore W2947559080C29730261 @default.
• W2947559080 hasConceptScore W2947559080C31760486 @default.
• W2947559080 hasConceptScore W2947559080C530470458 @default.
• W2947559080 hasConceptScore W2947559080C55493867 @default.
• W2947559080 hasConceptScore W2947559080C71924100 @default.
• W2947559080 hasConceptScore W2947559080C86554907 @default.
• W2947559080 hasConceptScore W2947559080C90924648 @default.
• W2947559080 hasConceptScore W2947559080C99454951 @default.
• W2947559080 hasIssue "15_suppl" @default.
• W2947559080 hasLocation W29475590801 @default.
• W2947559080 hasOpenAccess W2947559080 @default.
• W2947559080 hasPrimaryLocation W29475590801 @default.
• W2947559080 hasRelatedWork W1968731610 @default.
• W2947559080 hasRelatedWork W1981180604 @default.
• W2947559080 hasRelatedWork W2074517075 @default.
• W2947559080 hasRelatedWork W2115964437 @default.
• W2947559080 hasRelatedWork W2154590531 @default.
• W2947559080 hasRelatedWork W2163467469 @default.
• W2947559080 hasRelatedWork W2171002327 @default.
• W2947559080 hasRelatedWork W2329107753 @default.
• W2947559080 hasRelatedWork W2468666928 @default.
• W2947559080 hasRelatedWork W4255321854 @default.
• W2947559080 hasVolume "37" @default.
• W2947559080 isParatext "false" @default.

• next